X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Swift Launches Accel-Amplicon Custom NGS Panels, Accelerating Variant Discovery in Challenging Biological Samples

Yuvraj_pawp by Yuvraj_pawp
13th October 2017
in Research & Development

Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing announced the launch of its Accel-Amplicon™ Custom NGS Panels.

These new panels offer a targeted DNA sequencing product that enables clinical researchers to rapidly design highly focused panels to discover, validate and screen disease genes and their variants.

With the quickest workflow, Swift’s Accel-Amplicon Custom NGS Panel is a powerful solution to discover and assess clinically-relevant mutations across targeted genes using multiplexed amplicon sequencing. The panel is platform agnostic and addresses many applications such as fine mapping, variant discovery and screening, post GWAS replication, drug target discovery, clinical trial management and monitoring therapeutic efficacy.


“Our Accel-Amplicon Custom NGS Panels offer a breakthrough for translational researchers to interrogate variants within sample types that were impractical until now,” said Candia Brown, Swift’s Vice President of Global Marketing. “We’ve taken everything we’ve learned from our pre-designed panels and collaborative partnerships to deliver a transformative workflow that helps any laboratory implement targeted sequencing and rapidly uncover new biological insights into complex diseases.”


Key features and benefits of the Accel-Amplicon Custom NGS Panel include:

  • Supports the widest range of input sample types including fresh and fresh-frozen tissue, whole blood, blood spot cards, FFPE, cell-free DNA, circulating tumor DNA, buccal swab, whole genome amplified DNA and purified DNA.
  • Requires the least amount of sample input with only 10 nanograms
  • Enables the fastest library prep workflow in under two hours
  • Provides the only single-tube NGS assay with complete and comprehensive genomic coverage
  • Includes fully optimized and wet-lab validated NGS assays in every design.
  • Supported on either Ion Torrent™ or Illumina® sequencing platforms

To complete this breakthrough workflow, Swift partnered with Genialis, a software solution company, to integrate alignment, trimming, QC and variant calling into one simple pipeline. The Genialis’ cloud application also automates an algorithm optimized for accurate variant detection, including low frequency variants in heterogeneous samples, such as cancer. It is fast and easy to use, as it offers data visualization and annotated variants using direct links to publicly available databases such as COSMIC and NCBI.

“Targeted NGS sequencing is transforming translational research and genomic medicine by allowing researchers to rapidly and confidently screen important variants,” said Rafael Rosengarten, Genialis’ President and Chief Product Officer. “However, data analysis and interpretation is a long-standing bottleneck that has significantly constrained the speed and scale of these studies. This alliance with Swift Biosciences will enable us to deliver our innovative algorithms and interface to transform how researchers call, visualize and annotate variants. This will yield faster discoveries and support broader collaboration between laboratories.”

The Accel-Amplicon Custom NGS Panel is now commercially available. At ASHG 2017, Swift and Genialis will debut the complete targeted sequencing workflow at a Swift educational workshop on October 19. The event, entitled “Harnessing the Power of Next-Generation Sequencing for Precision Medicine” will be held at the Hilton Orlando Hotel, Lake George Ballroom.


About Swift Biosciences

Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis. Swift Biosciences’ products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences®, Illumina® and Ion Torrent™.

 

The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.

Previous Post

Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy In Metastatic Prostate Cancer Patients

Next Post

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In